rdf:type |
|
lifeskim:mentions |
umls-concept:C0002085,
umls-concept:C0019721,
umls-concept:C0030956,
umls-concept:C0039195,
umls-concept:C0205263,
umls-concept:C0376358,
umls-concept:C0392959,
umls-concept:C0456387,
umls-concept:C1364020,
umls-concept:C1424600,
umls-concept:C1516213,
umls-concept:C2698977
|
pubmed:issue |
2
|
pubmed:dateCreated |
2009-1-16
|
pubmed:abstractText |
We previously reported the SART3 gene to be a tumor-rejection antigen gene encoding a peptide at positions 109-118 (SART3(109-118)) with the ability to induce HLA-A24-restricted cytotoxic T lymphocytes. In this study, we investigated both humoral and cellular responses to this peptide in cancer patients with alleles other than HLA-A24 to explore the possibility of using this peptide as a cancer vaccine for these patients. IgG reactive to SART3(109-118) peptide was identified in sera of the vast majority of non-cancer subjects (n=50) and all cancer patients (n=50) tested without apparent HLA-A association. Levels of anti-SART3(109-118) peptide antibody in cancer patients were significantly higher than those of non-cancer subjects, but no difference was found between HLA-A24+A2- and HLA-A24-A2+ cancer patients. This peptide induced cancer cell-reactive cytotoxic T lymphocytes from peripheral blood mononuclear cells of both healthy donors and prostate cancer patients with HLA-A11, HLA-A31 and HLA-A33 alleles, but not with HLA-A2. These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Actins,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/RNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/SART3 protein, human
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1019-6439
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
529-36
|
pubmed:meshHeading |
pubmed-meshheading:19148489-Actins,
pubmed-meshheading:19148489-Amino Acid Sequence,
pubmed-meshheading:19148489-Antigens, Neoplasm,
pubmed-meshheading:19148489-Cell Line, Tumor,
pubmed-meshheading:19148489-DNA Primers,
pubmed-meshheading:19148489-HLA-A Antigens,
pubmed-meshheading:19148489-Histocompatibility Antigens Class I,
pubmed-meshheading:19148489-Humans,
pubmed-meshheading:19148489-Immunoglobulin G,
pubmed-meshheading:19148489-Leukocytes, Mononuclear,
pubmed-meshheading:19148489-Male,
pubmed-meshheading:19148489-Peptide Fragments,
pubmed-meshheading:19148489-Prostatic Neoplasms,
pubmed-meshheading:19148489-RNA-Binding Proteins,
pubmed-meshheading:19148489-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19148489-T-Lymphocytes, Cytotoxic
|
pubmed:year |
2009
|
pubmed:articleTitle |
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
|
pubmed:affiliation |
Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|